ArticleHealth affairs (Project Hope)2022
Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access.
Article in Health affairs (Project Hope), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Payers' Views on Expanding Their Role in Precision Medicine.JAMA network open · 2026Article
- Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.British journal of cancer · 2025Article
- Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.Journal of Alzheimer's disease : JAD · 2025Review
- Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.International journal of clinical oncology · 2025Review
- Clinical referral to the NHS following multi-cancer early detection test results from the NHS-Galleri trial.Frontiers in oncology · 2025Article
- Article
- Understanding the Landscape of Multi-Cancer Detection Tests: The Current Data and Clinical Considerations.Life (Basel, Switzerland) · 2024Review
- Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies.Journal of the National Cancer Institute · 2024Review
- Review
- Perspectives of primary care providers regarding multicancer early detection panels.Einstein (Sao Paulo, Brazil) · 2024Article
- Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening.Journal of personalized medicine · 2023Article
- Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests.Healthcare (Amsterdam, Netherlands) · 2023Article
- Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.Health affairs scholar · 2023Article
- Multi-cancer Early Detection Tests, Primary Care, and Shared Decision Making.Annals of internal medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
There is a tremendous public health need to identify potentially lethal cancers at earlier stages, when there is a greater chance for improved survival. Although in the US there are currently screening recommendations for only five cancers (breast, colorectal, cervical, lung, and prostate), new tests can screen for up to fifty cancers simultaneously based on a simple blood draw. However, these multicancer screening tests (also called "liquid biopsy" tests) will also present challenges to payers because of intrinsic features of the tests and the complexity of payer coverage assessments for screening tests. We describe these considerations while also offering potential solutions that can inform payers' decision making if these tests prove to be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.